Sanofi-a Ventis Deutschland Gmbh

Stefan Schaefer

Detlef Kozian

Sylvain Ricard

Sandrine Mace

Jean-Francois Deleuze

Karl-Ernst Siegler

Bernward Schoelkens

Hans-Ludwig Schaefer

Eugen Falk

Wolfgang Linz

The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.

Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism

The present invention is directed to a method identifying a risk for a thrombogenic disorder, to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.

Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-lle347 polymorphism

The invention describes the use of PPAR agonists of the formulae (I) or (II) for the treatment of congestive heart failure (CHF).

Use of PPAR agonists for the treatment of congestive heart failure

Growing community of inventors

Liederbach, Germany

Stefan Schaefer